ArriVent Biopharma Inc., a clinical-stage biopharmaceutical company, has announced the pricing of a $75 million public offering of common stock and pre-funded warrants. The company has filed an automatic shelf registration statement on Form S-3ASR with the SEC, which became effective upon filing on February 3, 2025. The offering includes 2,482,692 shares of common stock priced at $19.50 each and pre-funded warrants for an additional 1,363,469 shares. The proceeds are intended to support the company's pipeline programs and general corporate purposes. The offering, expected to close around July 3, 2025, is managed by Goldman Sachs, Citigroup, and Guggenheim Securities, among others.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ArriVent Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-065386), on July 02, 2025, and is solely responsible for the information contained therein.